Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; Nightingale/Prevent Breast Cancer Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK; Manchester Breast Centre, Manchester Cancer Research Centre, The Christie Hospital, Manchester, UK.
Breast. 2023 Feb;67:71-77. doi: 10.1016/j.breast.2023.01.003. Epub 2023 Jan 10.
Polygenic Risk Scores (PRS) are a major component of accurate breast cancer risk prediction and have the potential to improve screening and prevention strategies. PRS combine the risk from Single nucleotide polymorphisms (SNPs) associated with breast cancer in Genome Wide Association Studies (GWAS) and explain over 30% of breast cancer heritability. When incorporated into risk models, the more personalised risk assessment derived from PRS, help identify women at higher risk of breast cancer development and enables the implementation of stratified screening and prevention approaches. This review describes the role of PRS in breast cancer risk prediction including the development of PRS and their clinical application. We have also examined the role of PRS within more well-established risk prediction models which incorporate known classic risk factors and discuss the interaction of PRS with these factors and their capacity to predict breast cancer subtypes. Before PRS can be implemented on a population-wide scale, there are several challenges that must be addressed. Perhaps the most pressing of these is the use of PRS in women of non-White European origin, where PRS have been shown to have attenuated risk prediction both in discrimination and calibration. We discuss progress in developing and applying PRS in non-white European populations. PRS represent a significant advance in breast cancer risk prediction and their further development will undoubtedly enhance personalisation.
多基因风险评分(PRS)是准确预测乳腺癌风险的主要组成部分,具有改善筛查和预防策略的潜力。PRS 结合了全基因组关联研究(GWAS)中与乳腺癌相关的单核苷酸多态性(SNP)的风险,并解释了超过 30%的乳腺癌遗传率。当纳入风险模型时,PRS 衍生的更个性化的风险评估有助于识别乳腺癌发病风险较高的女性,并能够实施分层筛查和预防方法。这篇综述描述了 PRS 在乳腺癌风险预测中的作用,包括 PRS 的开发及其临床应用。我们还研究了 PRS 在更成熟的风险预测模型中的作用,这些模型纳入了已知的经典风险因素,并讨论了 PRS 与这些因素的相互作用及其预测乳腺癌亚型的能力。在 PRS 能够在全人群中实施之前,必须解决几个挑战。其中最紧迫的问题是在非白种欧洲血统的女性中使用 PRS,因为 PRS 在区分和校准方面都显示出风险预测减弱。我们讨论了在非白种欧洲人群中开发和应用 PRS 的进展。PRS 代表了乳腺癌风险预测的重大进展,它们的进一步发展无疑将增强个性化。